Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers by Ræder, Maria B. et al.
Integrated Genomic Analysis of the 8q24 Amplification
in Endometrial Cancers Identifies ATAD2 as Essential to
MYC-Dependent Cancers
Maria B. Raeder1,2,3*, Even Birkeland1,2, Jone Trovik1,2, Camilla Krakstad1,2, Shyemaa Shehata3,
Steven Schumacher3,4, Travis I. Zack3,4,5, Antje Krohn6, Henrica M.J. Werner1,2, Susan E. Moody3,4,
Elisabeth Wik1,2, Ingunn M. Stefansson7,8, Frederik Holst6, Anne M. Oyan7,9, Pablo Tamayo4,
Jill P. Mesirov4, Karl H. Kalland7,9, Lars A. Akslen7,8, Ronald Simon6, Rameen Beroukhim3,4,10.,
Helga B. Salvesen1,2.
1Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway, 2Department of Clinical Medicine, University of Bergen, Bergen, Norway,
3Department of Cancer Biology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 4 The Broad
Institute, Cambridge, Massachusetts, United States of America, 5Department of Biophysics, Harvard University, Boston, Massachusetts, United States of America,
6Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg-Eppendorf, Germany, 7 The Gade Institute, University of Bergen, Bergen, Norway,
8Department of Pathology, Haukeland University Hospital, Bergen, Norway, 9Department of Microbiology and Immunology, Haukeland University Hospital, Bergen,
Norway, 10Departments of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
Abstract
Chromosome 8q24 is the most commonly amplified region across multiple cancer types, and the typical length of the
amplification suggests that it may target additional genes to MYC. To explore the roles of the genes most frequently
included in 8q24 amplifications, we analyzed the relation between copy number alterations and gene expression in three
sets of endometrial cancers (N = 252); and in glioblastoma, ovarian, and breast cancers profiled by TCGA. Among the genes
neighbouring MYC, expression of the bromodomain-containing gene ATAD2 was the most associated with amplification.
Bromodomain-containing genes have been implicated as mediators of MYC transcriptional function, and indeed ATAD2
expression was more closely associated with expression of genes known to be upregulated by MYC than was MYC itself.
Amplifications of 8q24, expression of genes downstream from MYC, and overexpression of ATAD2 predicted poor outcome
and increased from primary to metastatic lesions. Knockdown of ATAD2 and MYC in seven endometrial and 21 breast cancer
cell lines demonstrated that cell lines that were dependent on MYC also depended upon ATAD2. These same cell lines were
also the most sensitive to the histone deacetylase (HDAC) inhibitor Trichostatin-A, consistent with prior studies identifying
bromodomain-containing proteins as targets of inhibition by HDAC inhibitors. Our data indicate high ATAD2 expression is a
marker of aggressive endometrial cancers, and suggest specific inhibitors of ATAD2 may have therapeutic utility in these
and other MYC-dependent cancers.
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Introduction
Endometrial carcinoma is the most common pelvic gynecologic
malignancy, with a lifetime risk among women of 2–3% [1].
Approximately 75% of tumors are confined to the uterine corpus
at diagnosis and are resected. However, 15%–20% of these tumors
relapse. These tumors, and tumors that are metastatic at
presentation, respond poorly to chemotherapy or radiation and
are generally fatal [1,2].
There is a need for novel markers to identify patients with high
risk of relapse, and to develop new therapies for patients with
metastatic disease [3,4]. Unfortunately, research towards these
goals is heavily underrepresented in endometrial cancer compared
to other cancer types such as breast and ovarian cancers. One
approach is to identify genes that, when altered by somatic genetic
events, drive tumor progression. These alterations can then serve
as markers of aggressive cancers and the genes can serve as
potential therapeutic targets.
The most frequent focal amplification in endometrial cancer is
on 8q24 [5]. Indeed, 8q24 is the most commonly amplified region
across multiple cancer types [6], and this amplification is a
negative prognostic marker in several cancers [7]. Although MYC
is a likely target [6], the effects of this amplification in endometrial
cancer have never been dissected. Indeed, it is possible that it
targets multiple genes, as has been shown for amplifications
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elsewhere in the cancer genome [8]. For example, a neighboring
gene, ATAD2, has been found to be a co-regulator of MYC and
overexpression of ATAD2 has been associated with poor prognosis
in breast, lung, and prostate cancers [9,10,11].
We explore the role of the 8q24 amplification in endometrial
cancer through integrative genomic analyses of primary and
metastatic endometrial cancers with comprehensive clinical data,
and identify ATAD2 as an additional target of the 8q24
amplification in these cancers. We identify copy number gain of
ATAD2 as a regulator of ATAD2 expression, present the first data
linking ATAD2 overexpression to MYC activation, and provide
functional data suggesting ATAD2 as a therapeutic target in
MYC-dependent cancers.
Materials and Methods
Ethics Statement
The collection of endometrial carcinoma primaries and
metastases for this study was approved by the Norwegian Data
Inspectorate (961478-2), Norwegian Social Sciences Data Services
(15501) and the ‘‘Regional Research Ethics.
Committee in Medicine, Western Norway’’ (reference 052.01).
All the participants gave written informed consent.
Patient Series
Endometrial carcinoma primaries and metastases were collected
from patients treated at Haukeland University Hospital, Norway
as previously described [5]. Tumors collected for the primary
investigation and qPCR validation series were frozen immediately
upon resection; tumors collected for FISH were formalin fixed and
paraffin embedded. Patients were followed from primary surgery
until October 2010 or death. The copy-number profiles of the
primary investigation series, and the expression profiles (Agilent
21 k and 22 k oligoarrays) from a subset of 57 tumors, were
published previously [5].
RNA Analysis
RNA was extracted and hybridized to Agilent 44K arrays
(Cat.no. G4112F) according to manufacturer’s instructions and as
previously described [5]. Signal intensities were evaluated using
BRB-ArrayTools (National Cancer Institute, USA). The arrays
were batch median normalized.
Real-time Quantitative PCR
cDNA was synthesized from 1 mg RNA using High capacity
RNA to cDNA kits (Applied Biosystems). Expression of ATAD2
and MYC was determined using TaqMan gene expression assays
Hs00204205 and Hs00905030 respectively (Applied Biosystems)
and all samples were run on microfluidic cards per manufacturer’s
instructuions, using GAPDH-Hs99999905_m1 as endogenous
control. Samples were run in triplicate and analyzed in RQ
manager (Applied Biosystems).
FISH
Tissue microarrays (TMAs) representing the highest-grade areas
in each tumor were prepared as previously reported [12] and
treated at 56Cu overnight before hybridization. FISH was done
using the MYC Spectrum Orange FISH probe kit and Chromo-
some enumeration probe 8 (CEP8) (Vysis) according to manufac-
turer’s instructions, as previously reported [13]. Counting was
performed in areas of optimal tissue digestion and no overlapping
nuclei. Probe and control signals were counted in 40–60 cells
within areas of optimal tissue digestion and no overlapping nuclei.
Amplifications were scored when the MYC/CEP8 ratio was.1.0.
TCGA Validation Dataset
We accessed level 3 data from the TCGA data portal in
November and December 2010. For breast cancer we obtained
gene expression data for 279 tumors and 24 normal controls
(Agilent 244K expression arrays), and copy-number from 176
tumors (Affymetrix SNP 6.0 Arrays). For ovarian cancer we
obtained gene expression (Agilent 244K expression arrays) and
copy-number (Agilent 1M arrays) data from 514 and 489 tumors,
respectively. For glioblastoma we obtained gene expression data
from 385 tumors and 10 normal controls (Affymetrix U133A
arrays) and copy-number data from 261 tumors (Agilent 244K
arrays).
Cell Viability
Lentiviral vectors encoding shRNAs specific for ATAD2, MYC,
and the controls GFP, LACZ1, and LACZ2 (Table S1) were
obtained from The RNAi Consortium. Lentivirus was produced
by transfection of 293T cells with vectors encoding each shRNA
(5 mg) with packaging plasmids encoding PSPAX2 and PDM2.G
using Fugene HD (Roche). Lentivirus-containing supernatant was
collected 48 and 72 h after transfection, pooled, and stored at
280 uC. Cells were infected in polybrene-containing media,
centrifuged at 1,000 g for 30 min, and selected in puromycin
(2.5 mg ml21) starting 24 h after infection.
Cancer cell lines were obtained from ATCC, DSMZ, ECACC
and HSRRB, and grown according to supplier’s instructions
(Table S2). Cell viability after RNAi was measured in 96-well
plates. Eight wells seeded with cells were infected using 1:30
dilutions of virus containing each shRNA. Half of the wells
underwent puromycin selection, and cell viability was measured
using Cell-Titer Glo (Promega) one week later. The values from
each quadruplicate were averaged; ‘‘outlier’’ wells were excluded if
the replicate wells had SD/mean .0.2 and excluding the well
improved the variance. The mean ATAD2- and MYC- hairpin
values were normalized to the mean values from the GFP control.
To determine Trichostatin-A sensitivity, Trichostatin-A (Sigma)
(0.040 to 10 mM) and vehicle (DMSO) control were each added to
three wells containing each cell line on 96-well plates. Cell viability
was determined after 72 hours using Cell-Titer Glo (Promega).
Immunoblotting
Cells were washed with PBS, harvested, lysed using RIPA lysis
buffer with protease and phosphatase inhibitors, and centrifuged
at 16,0006g. Supernatant was mixed with 4X SDS sample buffer,
boiled for 7 minutes, and subjected to SDS-PAGE on 4–12%
gradient gels. Blots were probed with antibodies against ATAD2
(HPA029424, Sigma), MYC (sc-764, Santa Cruz) and actin (sc-
1615, Santa Cruz).
Statistics
Molecular data was related to clinical phenotype using
Pearson’s x2 or two-sided Student’s t test as appropriate. We
used multivariate linear regression analysis for the prediction of
ATAD2 expression levels. Univariate and multivariate survival
analyses were performed by log rank and Mantel-Cox methods,
respectively. ‘‘MYC signaling strength’’ and gene expression levels
were presented as Z-scores.
Results
Assessment of MYC as a Target of the 8q24 Amplification
Extensive biological data support MYC as an oncogene [14],
and 8q24, harboring MYC, is the most common amplified region
ATAD2 as Essential to MYC-Dependent Cancers
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across multiple cancer types [6]. However, the importance of
MYC activation in endometrial cancer is essentially unknown.
We performed an integrated analysis of copy-number and
expression data to look for evidence that MYC is a target of 8q24
amplification in endometrial cancer. We evaluated expression data
from a series of 82 endometrial cancers obtained in a single county
in Norway, with corresponding genome-wide copy-number data
from 70 tumors (the ‘‘primary investigation series’’). Sixteen of
these tumors (23%) had 8q24 amplification. Most of these
amplifications were low-level, ranging up to a copy-number of
4.7. We validated our results in four additional datasets. Two of
these represent samples with genome-wide expression profiling: an
‘‘internal validation series’’ for which we generated data from 40
primary and 19 metastatic endometrial cancers recruited from the
same region in Norway, and an ‘‘external validation series’’
representing previously published expression profiles from 111
tumors [5]. The other two validation sets represent samples
analyzed with focused assays: a ‘‘qPCR series’’ of 162 samples and
a ‘‘FISH series’’ of 399 samples. Patient characteristics and
histopathological variables for all of our internal datasets are
shown in Table S3.
We found that both MYC and genes upregulated by MYC were
overexpressed in endometrial cancers with 8q24 amplification
relative to endometrial cancers without it (p = 0.047 and
p= 0.0078, respectively) (Figures 1a–b). We used a previously
published list of 68 genes found to be upregulated by MYC across
multiple contexts and assays (Table S4; www.myccancergene.org)
[15] and scored their overexpression (‘‘MYC signaling strength’’)
using GSEA [16]. We also tested five additional MYC activation
signatures obtained from the ‘‘Gene Set Enrichment Database’’,
reflecting the activation of MYC in different contexts. Four of
these were expressed at higher levels in endometrial cancers with
8q24 amplification (Figure S1a).
However, variations in MYC expression itself only explained a
small proportion of variations in MYC signaling strength
(R2= 0.11, p= 0.002) (Figure S1b). We obtained similarly weak
results in the internal and external validation datasets (R2= 0.00,
p = 0.34 and R2=0.06, p = 0.012, respectively; Figure S1b).
Across all three datasets, variations in MYC expression only
account for 5% of variations in MYC signaling strength
(R2= 0.05, Figure 1c).
Moreover, 8q24 amplifications are longer than the typical
distribution of amplification sizes in endometrial cancer
(p = 0.0021) (Figure 1c), and usually involve multiple genes. We
therefore hypothesized that 8q24 amplifications may target
additional genes, some of which may function through increasing
MYC signaling. To identify these, we evaluated all 26 genes in the
peak region of amplification on 8q24 for which we had expression
data, to identify genes whose expression correlated most strongly
with amplification.
Expression of ATAD2 Correlates Strongly with 8q24
Amplification and MYC Signaling
Expression of ATAD2 was more strongly associated with
amplification of 8q24 than was expression of any other gene in
the peak region of the amplification (p-value = 2.77E-06)
(Figure 1d). Four other genes, NDUFB9, DERL1, FAM91A1, and
WDR67, were significantly upregulated by 8q24 amplification,
though less strongly than ATAD2.
Expression of ATAD2 also correlated with MYC signaling
strength more strongly than did expression of any other gene in
the 8q24 peak region (R2= 0.48, p,0.001; Figure 1e, Figure S1b).
Indeed, the association between ATAD2 expression and MYC
signaling strength was observed even among samples without 8q24
amplification (R2=0.48, p,0.001). The correlation between
ATAD2 expression and MYC signaling strength was more than
twice as strong as the next most significantly associated gene
(NDUFB9) and stronger than for MYC itself (R2= 0.05; Figure 1c).
ATAD2 is not one of the 68 genes in the MYC activation signature,
and to our knowledge MYC has not been found to modulate
expression of ATAD2 [15]. However, ATAD2 was previously
found to bind to MYC and to the E-box region of several MYC
target genes, and ATAD2 levels were found to be limiting for
MYC-dependent transcription [9].
Both genome-wide validation series also exhibited the correla-
tion between MYC signaling and ATAD2 expression (R2=0.54,
p,0.001 and R2= 0.45, p,0.001 in the internal and external
validation series, respectively) and the relative lack of correlation
with MYC expression (R2= 0.00, p = 0.33 and R2=0.06,
p = 0.012; Figures 1f and S1b). Expression of ATAD2 also
correlated with four of the five additional signatures of MYC
activation, and correlated more strongly with these signatures than
did expression of MYC itself (Table 1). The last signature showed
no association with ATAD2 or MYC expression.
Amplification of 8q24 and Expression of ATAD2, but not
MYC, are Associated with Disease Progression
Among the 70 endometrial cancers for which we had genome-
wide SNP array data, 8q24 amplification was associated with
reduced progression-free survival (p = 0.024) and increased risk for
disease-specific death (p = 0.043). Amplification of 8q24 was most
frequent in non-endometrioid (p = 2.98E-05) and high-grade
tumors (p = 2.90E-08) (Table S5), features also associated with
aggressive cancers [17].
We confirmed 8q24 amplification is associated with poor
prognosis using FISH in an independent series of 399 endometrial
cancers. Twenty cancers (5%) exhibited increased 8q24 copy-
numbers relative to the chromosome 8 centromere (Figure 2a).
These were associated with 64% 5-year survival, vs. 85% for
cancers without 8q24 amplification (p,0.001) (Figure 2b). A
similar pattern was seen for recurrence free survival (p = 0.001).
Amplification of 8q24 was also associated with high FIGO stage
(p = 0.003), non-endometrioid histological subtype (p,0.001), and
high grade (p,0.001) (Table S5).
High expression of ATAD2 and MYC signaling were also
associated with increased risk of cancer progression (p= 0.003 and
p= 0.015, respectively), cancer-specific death (p= 0.004 and
p= 0.001) (Figures 2c–d), and other poor-prognosis features.
ATAD2 expression was higher in non-endometrioid, high-grade
and ER negative tumors (p,0.001, p,0.001, and p= 0.02
respectively; Table S6); high MYC signaling was associated with
poorly differentiated (p = 0.0016) and non-endometrioid
(p,0.001) cancers. Expression of ATAD2 was also negatively
associated with expression of ESR1 (R2= 0.10, p = 0.005).
Similarly, prior studies have found that ATAD2 expression is
higher in triple negative breast cancer tumors [18] and is
downregulated by estrogen in cell culture [19].
Indeed, ATAD2 expression was an independent predictor for
disease-specific death (HR=1.83, p = 0.027) and disease progres-
sion (HR=1.62, p = 0.011) after adjusting for ER status. ER-
negative tumors with upper-quartile ATAD2 expression were
particularly lethal (HR=4.1, p = 0.002; Figure 2e).
We confirmed these results by assessing ATAD2 expression by
quantitative PCR and ER status by immunohistochemistry in our
qPCR validation series of 162 additional tumors. Among these,
ER-negative tumors with upper-quartile ATAD2 expression were
associated with even worse outcomes than in the primary series
(HR=6.8, p,0.001) (Figure S1c). High ATAD2 expression also
ATAD2 as Essential to MYC-Dependent Cancers
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remained associated with increased risk of disease-specific death
(p = 0.0043) and shorter progression-free survival (p = 0.016). After
adjusting for ER status, ATAD2 expression continued to predict
disease-specific death (HR=1.86, p= 0.018) but only trended
towards an association with disease progression (HR=1.31,
p = 0.11). Expression of ATAD2 was also higher in high-grade
(p,0.001), non-endometrioid (p = 0.005), and ER-negative tumors
(p = 0.02) (Table S6).
In contrast,MYC expression was not associated with progression
or risk of disease-specific death in either our primary investigation
series (p = 0.07 and p=0.68 respectively) or the qPCR validation
series (p = 0.53 and p=0.28 respectively). High expression ofMYC
was associated with high grade in both series (p,0.001 and
p= 0.02, respectively), and with non-endometrioid histology in the
primary investigation series (p = 0.03) (Table S6).
Metastases also exhibit more 8q24 amplification, ATAD2
expression, and MYC signaling strength than primary tumors.
Relative to primary tumors, metastases exhibited 2.46higher rates
of focal 8q24 amplification by FISH (14.3%; p,0.007). Among
the 399 patients in the FISH series, 49 had paired primary and
metastatic tumors. Five of these samples (10%) did not exhibit
8q24 amplification in the primary but acquired it in the metastasis.
Only one sample (2%) exhibited the opposite pattern. To examine
ATAD2 expression and MYC signaling, we also compared the 42
primary tumors with the 19 metastases in our internal validation
series. Both ATAD2 expression and MYC signaling strength were
higher in the metastases (p = 0.002 and 0.004 respectively;
Figure 2f–g), including among 8 patients with paired primary
tumors and metastases (p = 0.01 and 0.05 respectively).
Extension to Other Cancer Types and Normal Tissue
We also investigated whether 8q24 amplification is associated
with increased ATAD2 expression in other cancer types. Specif-
ically, we used data from 514 ovarian cancers, 279 breast cancers,
and 385 glioblastomas from The Cancer Genome Atlas [20,21].
These included expression data from adjacent normal tissue for 24
breast cancers and 10 glioblastomas. 8q24 amplifications were
observed in 72% (N=126) of the breast cancers, 74% (N=364) of
the ovarian cancers, and 10% (N=27) of the glioblastomas.
ATAD2 was co-amplified to the same level as MYC in nearly all
tumors (as it was among our endometrial cancers; Figure S1d–g).
Expression of ATAD2 correlated with 8q24 amplification among
all three cancer types (R2= 0.47, 0.11, and 0.36 for breast cancers,
glioblastomas, and ovarian cancers respectively; p,0.001 in all
cases; Table S7), and was 2.66 and 2.56 higher among the
cancers relative to normal tissue in breast cancer and glioblastoma,
respectively (p,0.001 in both cases). MYC expression correlated
less strongly with 8q24 amplification in all three cancer types
(R2= 0.12, 0.07, and 0.10 for breast cancers, glioblastomas, and
ovarian cancers respectively; p,0.001 in all cases). MYC
expression in breast cancers was surprisingly half that of normal
tissue (p,0.001); in glioblastoma it was higher by a factor of 3.5
(p,0.001).
ATAD2 expression also correlated with MYC signaling in all
three cancer types (R2= 0.11, 0.21, and R2=0.31, respectively for
Figure 1. MYC, ATAD2 and 8q24 associations. (a) MYC expression and (b) MYC signaling are both increased among endometrial cancers with
8q24 amplification. (c) Variations in MYC expression only explain a small proportion of the variation in MYC signaling. Linear fits are shown in red,
yellow, and green for the primary investigation series, internal validation series, and external validation series, respectively. (d) The lengths of the
amplifications that contain MYC are significantly larger than expected compared to amplifications observed elsewhere in these cancers. (e) Among 26
genes in the 8q24 peak with corresponding expression data, expression of ATAD2 is most strongly and significantly associated with amplification.
Blue bars show the percent increase in gene expression and red bars show the p-values. The significance threshold is Bonferroni-corrected for
multiple hypotheses. (f) Expression of ATAD2 is highly correlated with MYC signaling strength. Linear fits are shown as in panel c.
doi:10.1371/journal.pone.0054873.g001
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breast cancers, glioblastomas, and ovarian cancers; p,0.001 in all
cases), and was more strongly correlated with MYC signaling
strength than MYC expression was (R2= 0.10, p,0.001;
R2= 0.09, p,0.001; and R2=0.02, p = 0.003 in the three cancer
types).
ATAD2 Expression is Correlated to E2F Gene Expression
and ATAD2 Copy Number in an Additive Manner
We also explored the relative contributions of E2F, estrogen,
and copy-number on ATAD2 expression. The ATAD2 promoter
region contains binding sites for several E2F proteins and previous
functional data have shown that E2F increases ATAD2 expression
in cell culture [9,22]; ATAD2 has also been induced by estrogen
[23]. In our data, expression of every E2F transcription factor was
associated with ATAD2 expression, but only the inclusion of E2F1,
E2F2 and E2F8 improved the overall fit of a model predicting
ATAD2 expression from ATAD2 copy-number and ESR1 expres-
sion. The expression levels of these three genes were highly
correlated, and we focused on E2F1.
We found that ATAD2 copy-number, ESR1 expression and
E2F1 expression explained 77% of the variation in ATAD2
expression in endometrial cancer, and each of the predictor
variables remained significantly associated with ATAD2 expression
in the adjusted model (Figure 3a and Table S7). We also found
that ATAD2 copy-number and E2F expression independently
predicted ATAD2 expression in breast cancer, ovarian cancer and
glioblastoma (Figure 3b–d and Table S7). ESR1, which was less
strongly associated with ATAD2 expression, was significant in the
adjusted model only in endometrial cancer (p = 0.016) and
glioblastoma (p,0.001), not in ovarian or breast cancer. These
data suggest that the copy-number of ATAD2 is an important
determinant of ATAD2 expression even in the context of other
cellular regulatory mechanisms.
Dependency on MYC Predicts Dependency on ATAD2
and Response to HDAC Inhibitors in Endometrial- and
Breast Cancer Cells
The results above led us to hypothesize that ATAD2 expression
promotes MYC signaling and that endometrial cancer cells that
are dependent upon MYC would also be dependent upon ATAD2.
We measured the effect on viability of shRNA knockdowns of
ATAD2 and MYC in seven endometrial cancer cell lines. We used
two shRNAs against each gene, selecting those that exhibited the
greatest reduction of protein expression among six and three
shRNAs screened against ATAD2 andMYC respectively (Figure 4a,
b).
Knockdown of either ATAD2 or MYC resulted in highly
correlated decreases in viability across the seven cell endometrial
cancer lines (R2= 0.70, p = 0.020; Figure 4c). In two cases, we
observed over 75% reductions in viability. We found no
Table 1. Associations between other MYC activation gene sets and ATAD2- and MYC expression.
ATAD2 MYC
Gene set R2 P-value P-value* R2 P-value P-value*
Schumacher myc up{ 0.45 ,0.001 ,0.001 0.11 ,0.001 0.001
Primary Investigation Series 0.43 ,0.001 ,0.001 0.16 ,0.001 0.025
Internal validation Series 0.38 ,0.001 ,0.001 0.05 0.800 0.252
External validation Series 0.5 ,0.001 ,0.001 0.49 ,0.001 0.026
Coller myc up{ 0.35 ,0.001 ,0.001 0.10 ,0.001 0.002
Primary Investigation Series 0.36 ,0.001 ,0.001 0.19 ,0.001 0.006
Internal validation Series 0.22 ,0.001 0.001 0.03 0.186 0.427
External validation Series 0.43 ,0.001 ,0.001 0.10 0.001 0.08
Yu cmyc up1 0.62 ,0.001 ,0.001 0.05 ,0.001 0.987
Primary Investigation Series 0.62 ,0.001 ,0.001 0.06 0.290 0.612
Internal validation Series 0.68 ,0.001 ,0.001 0.02 0.252 0.973
External validation Series 0.60 ,0.001 ,0.001 0.07 0.006 0.632
Myc oncogenic signature" 0.20 ,0.001 ,0.001 0.23 ,0.001 ,0.001
Primary Investigation Series 0.27 ,0.001 ,0.001 0.19 ,0.001 0.004
Internal validation Series 0.08 0.042 ,0.001 0.32 ,0.001 0.133
External validation Series 0.24 ,0.001 ,0.001 0.22 ,0.001 ,0.001
Lee myc up|| 0.05 ,0.001 0.001 0.02 0.150 0.147
Primary Investigation Series 0.02 0.175 0.175 0.00 0.825 0.79
Internal validation Series 0.00 0.656 0.587 0.00 0.612 0.553
External validation Series 0.18 ,0.001 ,0.001 0.18 0.002 0.051
R2 and p-values are derived from a linear regression of the sum of expression values within the gene set against ATAD2 or MYC expression.
*Adjusted for ATAD2 or MYC expression.
{Genes up-regulated in P493-6 cells (Burkitt’s lymphoma) induced to express MYC (Schumacher).
{Genes regulated by forced expression of MYC in 293T (transformed fetal renal cell).
1Genes up-regulated in B cell lymphoma tumors expressing an activated form of MYC.
"Genes selected in supervised analyses to discriminate cells expressing c-Myc from control cells expressing GFP. Myc oncogeneic.
||Genes up-regulated in hepatocellular carcinoma (HCC) induced by overexpression of MYC.
doi:10.1371/journal.pone.0054873.t001
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association between expression of ATAD2 or MYC or 8q24 copy
number and sensitivity to ATAD2 or MYC knockdown.
These results suggested that MYC-dependent cancers of other
types might also be dependent on ATAD2. No decrease in
proliferation had previously been seen with ATAD2 knockdown in
TIG3-T or U2OS cells [9]. When we tested a larger panel of 21
breast cancer lines, however, we confirmed the strong correlation
between decrease in viability after knockdown of ATAD2 or MYC
(R2= 0.61, p,0.001; Figure 4d).
The association between dependency on MYC and ATAD2
suggests ATAD2 as a therapeutic target in MYC-dependent
cancers. Whereas MYC has long been a known oncogene, clinical
approaches to block MYC signaling have not yet been successful.
Histone deacetylase (HDAC) inhibitors, however, have been
shown to indirectly inhibit bromodomain-containing proteins such
as ATAD2 [24].
We used the Connectivity Map [25] to identify compounds
whose signatures anticorrelated with the MYC signaling signature.
Among the 1309 small molecules represented by the Connectivity
Map, the signature of the HDAC inhibitor Trichostatin-A was
most anticorrelated with the MYC signaling signature. (p-
value,0.00001; Table S8). We also generated a signature of
aggressive disease from the primary investigation series, using the
50 most over- and under-expressed genes in patients with
metastatic disease compared to patients without metastatic disease.
We found the Trichostatin-A signature was also the most
anticorrelated with this signature of aggressive disease, tied with
signatures of four other molecules (p,0.00001; Table S8).
To functionally confirm the relation between Trichostatin-A
and MYC dependency, we tested all endometrial cancer and
Figure 2. Amplification of 8q24, ATAD2 overexpression and increasedMYC signaling are associated with poor prognosis. FISH probes
against 8q24 (red) and the chromosome 8 centromere (green) in a primary tumor and the paired metastasis show amplification only in the latter (a)
(b) Among 399 patients assessed by FISH, those with 8q24 amplifications have worse outcome. In the primary investigation series, tumors among the
highest quartiles of (c) ATAD2 expression and (d) MYC signaling strength also had increased risk of disease-specific death. (e) Estrogen receptor
negative (ER2) tumors with ATAD2 expression in the top quartile were also associated with a high risk of disease-specific death; the risk was much
lower among estrogen receptor positive (ER+) tumors with ATAD2 expression in the bottom quartile. (f) ATAD2 expression and (g) MYC signaling are
both higher among metastases than primary tumors in the internal validation series.
doi:10.1371/journal.pone.0054873.g002
Figure 3. 3-D-plots showing ATAD2 expression and -copy-
number and E2F1 expression. (a) Endometrial cancer, (b) breast
cancer, (c) ovarian cancer, and (d) glioblastoma. Yellow dots represent
the samples and the blue plate is the predicted 3-D fit. The green and
red lines are the distance between the predicted fit and the actual
observations for samples above and below the 3D-fit plate, respectively.
doi:10.1371/journal.pone.0054873.g003
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breast cancer cell lines for growth inhibition by Trichostatin-A and
compared the results toMYC knockdown. Trichostatin-A inhibited
growth in the same cell lines which were dependent on MYC both
in the endometrial (R2= 0.74, p= 0.013; Figure 4e), and in the
breast cancer cell lines (R2= 0.31, p= 0.007; Figure 4f) but the
overall efficacy of Trichostatin-A at reducing cell viability was
lower among the doses we tested (0.04–10 mM) (Table S9) than
were the effects of MYC or ATAD2 knockdown.
Discussion
Our data suggest that ATAD2 overexpression in human
endometrial cancers is a consequence of 8q24 amplification and
associated with MYC pathway activation. We also find that
ATAD2 overexpression is associated with E2F activation and poor
prognosis. Analyses of TCGA data suggest similar relationships
between ATAD2, 8q24 amplification, and MYC pathway activa-
tion in glioblastoma, breast, and ovarian cancers. We also find that
endometrial and breast cancer cell lines that are dependent upon
MYC expression also depend upon expression of ATAD2.
High expression of ATAD2 has previously been found to be
associated with an unfavorable prognosis in breast, lung, and
prostate cancers and it has been suggested that ATAD2
contributes to the development of aggressive cancer through
linking of the E2F and MYC pathways [9,10,11]. We demonstrate
an association between high ATAD2 expression and negative
outcome in endometrial cancer, using clinically well-characterized
test and validation datasets. We also find that progression from
primary to metastatic endometrial cancer is associated with a
further increase of MYC signaling and ATAD2 expression.
Ciro et al [9] previously showed that ATAD2 interacts with
MYC in breast cancer cell lines and is overexpressed in 8q24
Figure 4. Correlation between effects of ATAD2 and MYC knockdown. Western blots for (a) ATAD2 and (b) MYC indicate extent of
knockdown with six shRNAs against ATAD2 and three shRNAs against MYC, respectively. ATAD2 experiments were performed in KLE cells and MYC
experiments were performed in TE9 cells infected with GFP control and MYC vectors. Subsequent experiments used ATAD2 shRNAs a and e, and MYC
shRNAs a and b. Reductions in cell viability among seven endometrial cancer cell lines (c) and 21 breast cancer cell lines (d) were highly correlated
after knockdown of ATAD2 or MYC and after knockdown of MYC and treatment with the HDAC inhibitor Trichostatin-A (1.25 mM) (e–f).
doi:10.1371/journal.pone.0054873.g004
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amplified breast cancers. Our results indicate that, in endometrial
cancers, expression of ATAD2 is more highly correlated with 8q24
amplification than is expression of its neighbors (including MYC),
and that ATAD2 amplification and overexpression are strongly
associated with multiple measures of MYC pathway activation in
human tumors.
The finding of cooperative effects between MYC and coampli-
fied genes on 8q24 is not entirely surprising. Indeed, the concept of
oncogene cooperation was established through the study of
positive interactions between MYC and other oncogenes such as
BCL2 [26]. Moreover, clustered genes are often functionally
related [27]. The relevance of this phenomenon in cancer has
been shown for the genes MMP13, Birch2, and Birch3, which are
functionally related oncogenes contained on the same amplifica-
tion in osteosarcoma [28], and for BIRC2 and YAP1, cooperating
oncogenes in an amplification in hepatocellular carcinomas [8].
Such a mechanistic association between ATAD2 and MYC, and
the finding that MYC-dependent cells are sensitive to ATAD2
knockdown, suggest ATAD2 as a therapeutic target in MYC-
dependent cancers. Although MYC has long been known as an
oncogene [14] and is a promising drug target, it has not been
successfully targeted therapeutically. Small molecule inhibitors
have, however, been generated against other bromodomain-
containing proteins [29]. Indeed, inhibition of the bromodomain-
containing protein BRD4 has recently been suggested as an
alternative approach to targeting MYC [30]. HDAC inhibitors
also indirectly inhibit bromodomain-containing proteins by
inducing histone hyperacetylation, thus probably diverting the
specific bromodomain proteins from their targets [24]. This may
account for some of the effectiveness of HDAC inhibitors as cancer
therapeutics [30], and we found cell lines that were sensitive to
knockdown of MYC or ATAD2 were also sensitive to the HDAC
inhibitor Trichostatin-A. However, the reduction in viability after
application of Trichostatin-A was smaller than the reduction in
viability after MYC or ATAD2 knockdown. It is possible that a
more direct inhibitor of ATAD2 would be more effective in these
cells.
Major obstacles to treatment of patients with endometrial
cancer include a lack of targeted therapeutics and of prognostic
indicators. Indeed, endometrial cancer remains understudied
relative to other cancer types. We find that ATAD2 amplification
and expression is a prognostic marker in endometrial cancer and
our findings suggest that development of specific ATAD2
inhibitors is a promising approach to treatment of endometrial
and other MYC driven cancers.
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